Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer

Diseases of the Esophagus

Volumn 28, Issue 4, 2015, Pages 358-364

  Hamai, Y ^a   Hihara, J ^a   Taomoto, J ^a   Yamakita, I ^a   Ibuki, Y ^a   Okada, M ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Complication; Esophageal cancer; Esophagectomy; Neoadjuvant therapy; Survival

Indexed keywords

CISPLATIN; CREATININE; DOCETAXEL; FLUOROURACIL; NEDAPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; BLEEDING; BODY MASS; CANCER MORTALITY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CERVICAL LYMPH NODE; CHYLOTHORAX; CONTROLLED STUDY; EMPYEMA; ENTERITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GRAFT NECROSIS; HEART ARRHYTHMIA; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; OPERATION DURATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASTIC SURGERY; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE PALSY; RESPIRATORY FAILURE; SENESCENCE; SURGICAL APPROACH; SURGICAL MORTALITY; SURVIVAL RATE; THERAPY EFFECT; WOUND INFECTION; ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NECK; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECK; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84928588048     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12207     Document Type: Article

References (31)

1. Sjoquist K M, Burmeister B H, Smithers B M etal. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
2. Gebski V, Burmeister B, Smithers B M, Foo K, Zalcberg J, Simes J. Australasian Gastro-Intestinal Trials Group: survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
3. van Hagen P, Hulshof M C, van Lanschot J J etal. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
4. Urschel J D, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
5. Fiorica F, Di Bona D, Schepis F etal. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930.
6. Bailey S H, Bull D A, Harpole D H etal. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 2003; 75: 217-222.
7. Reynolds J V, Ravi N, Hollywood D etal. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006; 132: 549-555.
8. Bosset J F, Gignoux M, Triboulet J P etal. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
9. Avendano C E, Flume P A, Silvestri G A, King L B, Reed C E. Pulmonary complications after esophagectomy. Ann Thorac Surg 2002; 73: 922-926.
10. Lin F C, Durkin A E, Ferguson M K. Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg 2004; 78: 1783-1789.
11. Kelley S T, Coppola D, Karl R C. Neoadjuvant chemoradiotherapy is not associated with a higher complication rate versus surgery alone in patients undergoing esophagectomy. J Gastrointest Surg 2004; 8: 227-231.
12. Merritt R E, Whyte R I, D'Arcy N T, Hoang C D, Shrager J B. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg 2011; 92: 2034-2040.
13. Berger A C, Scott W J, Freedman G etal. Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer. Semin Oncol 2005; 32: S16-20.
14. Walsh T N, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
15. Sato N, Kusama A, Ohkawa A etal. Resting energy expenditure in patients undergoing transhiatal or transthoracic oesophagectomy for carcinoma of the thoracic oesophagus. Br J Surg 1993; 80: 1413-1415.
16. Viklund P, Lindblad M, Lu M, Ye W, Johansson J, Lagergren J. Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. Ann Surg 2006; 243: 204-211.
17. Boshier P R, Anderson O, Hanna G B. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg 2011; 254: 894-906.
18. Colvin H, Dunning J, Khan O A. Transthoracic versus transhiatal esophagectomy for distal esophageal cancer: which is superior? Interact Cardiovasc Thorac Surg 2011; 12: 265-269.
19. Chang A C, Ji H, Birkmeyer N J, Orringer M B, Birkmeyer J D. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85: 424-429.
20. Brinkman G L, Coates E O Jr. The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis 1963; 87: 684-693.
21. Hihara J, Yoshida K, Hamai Y, Emi M, Yamaguchi Y, Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 2007; 27: 2597-2603.
22. Emi M, Hihara J, Hamai Y etal. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol 2012; 69: 1499-1505.
23. Dindo D, Demartines N, Clavien P A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
24. Clavien P A, Barkun J, de Oliveira M L etal. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196.
25. Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 2009; 6: 71-94.
26. Tepper J, Krasna M J, Niedzwiecki D etal. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
27. Hirao M, Ando N, Tsujinaka T etal. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg 2011; 98: 1735-1741.
28. Birkmeyer J D, Siewers A E, Finlayson E V etal. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
29. Killeen S D, O'Sullivan M J, Coffey J C, Kirwan W O, Redmond H P. Provider volume and outcomes for oncological procedures. Br J Surg 2005; 92: 389-402.
30. Low D E. Evolution in perioperative management of patients undergoing oesophagectomy. Br J Surg 2007; 94: 655-656.
31. Hölscher A H, Vallböhmer D, Brabender J. The prevention and management of perioperative complications. Best Pract Res Clin Gastroenterol 2006; 20: 907-923.